Study calls for drug trial patients to receive more information about effects of placebos

Research carried out at the University of Southampton has concluded that participants in drug trials should be better informed about the potential significant benefits and possible side-effects of placebos.

Placebos are traditionally thought of as 'inert' , given in trials to act as a yardstick or constant by which to measure the effects of new 'active' drugs, known in clinical trials as the 'target treatment'. However, placebos themselves have been shown to create substantial health changes in patients.

"We believe the health changes associated with placebos should be better represented in the literature given to patients before they take part in a clinical trial. At the moment these effects are largely being ignored in the patient information leaflets," says lead researcher at Southampton and lecturer in , Dr Felicity Bishop.

She continues, "There is an important issue of consent here – patients should be fully aware of possible health changes from all treatments in a trial before agreeing to take part."

The research team, led by the University of Southampton in collaboration with Harvard Medical School and Northern Arizona University, examined the wording of 45 participant information leaflets from clinical trials which used placebos and are listed on the UK Clinical Research Network Database.

Analysis of the participant leaflets led to these key observations:

  • Emphasis was given to the target treatment being more desirable to receive than the .
  • Target treatments were widely described as 'real', 'genuine' and the focus of the study. Placebos were rarely described in their own right, rather they were mostly referred to in comparison to target treatments.
  • Target treatments were often described in relation to a class of , thus implying a particular effect, for example, antibiotics (infection fighting) or statins (cholesterol lowering).
  • Placebos were often described in negative terms, such as 'dummy' or 'fake'.
  • The leaflets emphasised both the benefits and adverse effects that might be triggered by the target treatment, but largely ignored any potential effects of the placebo.
Crucially, the study showed the target treatments were prioritised over the placebo, from the words in the leaflet titles, to the description of the trial process, through to explaining what would happen at the end of the trial.

Professor of Health Research at the University of Southampton, George Lewith, comments, "The leaflets largely ignored the overwhelming evidence that placebos can actually have significant and sustained effects on people. This could affect the treatment beliefs and expectations of those volunteering for studies and in turn the results.

"Studies at Southampton have clearly shown placebos can help about half of the people we treat with chronic pain and can be effective for a long time afterwards. The placebo effect works by releasing our bodies' own natural painkillers into our nervous system."

The researchers argue that volunteers for should be more fully informed about the health changes they might experience from a placebo, otherwise their informed consent, crucial to taking part, is in jeopardy. They believe different ways of describing placebos need to be developed and tested, both for participant information leaflets and for personal contact with those conducting research.

More information: To view the full paper, Informed Consent and Placebo Effects: A Content Analysis of Information Leaflets to Identify What Clinical Trial Participants Are Told About Placebos, visit: dx.plos.org/10.1371/journal.pone.0039661

add to favorites email to friend print save as pdf

Related Stories

Study evaluates placebo effectiveness

Feb 01, 2006

Harvard Medical School scientists who usually use placebos to test a new treatment's effectiveness have conducted a trial testing placebos.

The power of placebos

May 12, 2011

They may be uncomfortable talking about it, but it's definitely going on.

Placebos work -- even without deception

Dec 22, 2010

(PhysOrg.com) -- For most of us, the "placebo effect" is synonymous with the power of positive thinking; it works because you believe you're taking a real drug. But a new study rattles this assumption.

Internists say they prescribe placebos on occasion

Jan 03, 2008

In the first study examining American physicians' use of placebos in clinical practice in the 21st Century, 45 percent of Chicago internists report they have used a placebo at some time during their clinical practice researchers ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Temple
not rated yet Jun 28, 2012
When is somebody going to stick a bunch of people in an fMRI and see what areas of the brain are activated in the placebo group?

Hmm, that could lead to an interesting study. How would you build a study which distinguishes between a pill designed to activate the 'placebo centre' of the brain and one which is just a sugar pill?